Udvalget konkluderede imidlertid, at lægemidlet kun bør overvejes anvendt som ‘ sidste udvejs ’ behandling, når ingen andre proteasehæmmere forventes at virke.
However, the committee concluded that the medicine should only be considered for use as ‘ last line’ therapy, when no other protease inhibitors are predicted to work.